Home Latest Articles
Latest Articles
  • Qiang XUE, Wenli CAO, Lianhao FU
    World Clinical Drug. 2022, 43(5): 596-601.
    Objective

    To evaluate the clinical efficacy of self-made Ditan decoction combined with venlafaxine hydrochloride sustained-release capsule in the treatment of post-stroke somatization symptoms in patients with transient ischemic attack (TIA) and acute ischemic stroke (AIS).

    Methods

    A total of 120 patients with TIA and AIS in Tangshan Workers Hospital were randomly divided into treatment group and control group, and 60 cases in each group. The control group was treated with venlafaxine hydrochloride sustained-release capsule, and the treatment group was treated with self-made Ditan decoction on the basis of the control group. The scores and reduction rates of physical symptom group scale (PHQ-15), Hamilton depression scale (HAMD) and Hamilton anxiety scale (HAMA) of health questionnaire before treatment, 2, 4 and 6 weeks of treatment were compared between the two groups.

    Results

    There was no significant difference between the two groups (P>0.05). After treatment, with the extension of the cycle, the scores of HAMD, HAMA and PHQ-15 in the two groups decreased gradually, and the reduction range in the treatment group was greater than that in the control group. The difference between the two groups was statistically significant (P<0.05). The score reduction rates of HAMD and HAMA in the treatment group were higher than 50%, and that of PHQ-15 was higher than 25%, which was significantly different from that in the control group (P<0.05). The effective rates of HAMD, HAMA and PHQ-15 in the treatment group were 81.67%, 83.33% and 71.67% respectively, which were higher than those in the control group such as 61.76%, 63.33% and 55.00%. The difference between the two groups was statistically significant (P<0.05). The incidence of adverse reactions was 5.00% in the treatment group, when that was 3.33% in the control group. There was no significant difference in the incidence of adverse reactions (P>0.05).

    Conclusion

    The self-made Ditan decoction combined with venlafaxine hydrochloride sustained-release capsule is effective in the treatment of somatization symptoms in patients with TIA and AIS.

  • Zhonghua TIAN, Yuxia LI, Qin WANG, Mingchun HUANG
    World Clinical Drug. 2022, 43(5): 602-608.
    Objective

    To evaluate the efficacy of iguratimod (IGU) combined with methotrexate (MTX) on bone metabolism in rheumatoid arthritis (RA).

    Methods

    PubMed, Embase, Medline, Cochrane library, CNKI, WanFang Medical Online, VIP, and CBM were retrieved. The randomized controlled trial (RCT) was conducted. The literature quality was evaluated according to the Cochrane Handbook6.2 bias risk assessment tool, and the effect indicators were meta-analyzed using RevMan5.3 software.

    Results

    A total of 434 studies were retrieved, and 9 RCTs and 883 patients were included for meta-analysis. Compared with MTX monotherapy, IGU combined with MTX treatment could significantly improve the concentration of bone metabolism markers N-terminal midfragment of osteocalcin [mean difference (MD)=4.54, 95% confidence interval (CI)(4.09, 4.99), P<0.01], total N-terminal propeptide of type Ⅰ procollagen [MD=11.63, 95% CI (10.04, 13.21), P<0.01], β-C-terminal telopeptides of type Ⅰ collagen [MD=-0.22, 95% CI (-0.27, -0.18), P<0.01], and 25-hydroxy-vitamin D [MD=3.07, 95% CI (2.22, 3.92), P<0.01].

    Conclusion

    The combination of IGU and MTX is more effective than MTX monotherapy in improving the bone metabolism in RA patients. Subject to the quantitative and qualitative limitations of the studies included, more high-quality studies would be needed to further validate the results.

  • Huimi YU, Xueya MIN, Shiqi QIAO, Zhen GAO, Xuemin DI, Hongtao ZHANG
    World Clinical Drug. 2022, 43(5): 609-614.
  • Jiechun HUANG, Miao XIONG, Shizhen LUO, Danghong CHEN, Fang YAN
    World Clinical Drug. 2022, 43(5): 615-619.
  • Miao FANG, Degang WANG, Peiqing LIU
    World Clinical Drug. 2022, 43(5): 620-627.

    Dry eye disease (DED), also known as keratoconjunctivitis sicca (KCS), is a disease caused by unstable lacrimal gland secretion, which leads to abnormal tear quality or quantity and eye surface damage, resulting in a variety of ocular symptoms, such as inflammation, pain, redness and itching. DED can also induce by environmental and genetic factors. Although there are many kinds of drugs for DED on the market, the product penetration rate is low, so there is still a great demand in clinic. This paper reviewed the current clinical drug use of DED and the research progress of global drugs for DED in research, in order to provide reference for clinical drug use.

  • Xiaoyun YAN, Qiquan YU
    World Clinical Drug. 2022, 43(5): 628-632.

    Venous thromboembolism (VTE) has a high incidence in the perioperative period, including deep venous thrombosis (DVT) and pulmonary throm-boembolism (PTE). VTE is one of the common complications during perioperative period. Its symptoms are lack of specificity and clinical attention is not high. Therefore, it often leads to the failure of timely and effective prevention and treatment, which affects the postoperative safety of patients and even endangers their lives. This paper reviewed the clinical literature related to VTE in recent years, focusing on the incidence of VTE, operation related high-risk factors, prevention of integrated traditional Chinese and western medicine, in order to provide reference for clinical diagnosis and treatment.

  • Hongjiao MA, Xiaocui LI
    World Clinical Drug. 2022, 43(5): 633-637.

    Immune tolerance at the maternal-fetal interface plays an important role in maintaining pregnancy, and maternal immune dysfunction is one of the causes of abortion. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) not only act as an immune checkpoint, but also as one of the current research hotspots in maintaining immune balance during pregnancy. This article reviewed PD-1 and PD-L1 and their related factors in maintaining pregnancy and recurrent abortion, in order to provide a new reference on preventing abortion and maintaining immune tolerance in pregnancy.

  • Shuhui JU, Hengyu LI
    World Clinical Drug. 2022, 43(4): 347-351.

    The International Consensus Conference for Advanced Breast Cancer (ABC) is a premier international conference in breast cancer field organized by European School of Oncology (ESO) and European Society for Medical Oncology (ESMO). The conference aims to develop international consensus guidelines for the management of ABC patients, affect treatment decisions, prolong patients' overall survival, and improve patients' quality of life based on the latest evidence-based medical solutions. Breast cancer is divided into different subtypes on different hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status. HR positive/HER2 negative breast cancer is the most common. With the emergence of various novel candidates for endocrine and targeted therapies, optimal drug selection and appropriate arrangement is critical to the prolongation of patients' survival. November 2021, the Sixth International Consensus Conference for ABC was successfully held online, which provided guidance for the clinical practice. The article reviewed the updated key points and interpretation of HR positive/HER2 negative ABC part, in order to provide reference for the medication of ABC patients.

  • Shuie LI, Jinxi DING, Jiaming LI, Yuqing REN, Wei LI
    World Clinical Drug. 2022, 43(4): 352-358.

    As a novel cancer immunotherapy, chimeric antigen receptor T cell (CAR-T) therapy has good clinical efficacy but high treatment cost. Many foreign countries have included CAR-T in the medical insurance coverage to improve its affordability, however, CAR-T has not been included in National Reimbursement Drug List (NRDL) in China. By sorting the global CAR-T treatment status and medical insurance access situation, the paper summarized three difficulties for CAR-T access to NRDL, and proposed a three-stage solution of “independent payment of commercial health insurance-cooperative payment of commercial health insurance-regular payment of medical insurance”, providing reference to solve the CAR-T coverage problem in China.

  • Shengxin HUANG, Jinxi DING, Jiaming LI, Wei LI
    World Clinical Drug. 2022, 43(4): 359-368.

    Chimeric antigen receptor T cell (CAR-T) is a novel cancer immunotherapy, but it priced over a million yuan, so it has not been included in National Reimbursement Drug List (NRDL), resulting in its poor affordability. Under the background of multi-level healthcare security system, a small number of commercial health insurance companies in China have first explored the inclusion of CAR-T products in their coverage, which has reduced the burden of patients to a certain extent. The paper selected two mainstream commercial health insurance products, Urban Customized Commercial Health Insurance (UCCHI) and Million Medical Insurance product, as analysis objects. Furthermore, this paper, taking into account international experience and the development needs of Chinese commercial insurance, summarized the current coverage situation of CAR-T products, and proposed to optimize the design of commercial insurance products in four aspects: high premium, high benefit, long term and close connection, in order to provide better coverage for CAR-T products and other high-value innovative drugs with "good efficacy, high cost and uncertain population".

News